NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
Novartis’ Extavia is the only beta interferon being endorsed by the National Institute for Health and Care Excellence as a cost-effective treatment option for multiple sclerosis.